丘脑底核深部脑刺激对携带遗传风险因素/病因的帕金森病患者的影响研究
本研究比较了丘脑底核深部脑刺激(STN-DBS)在18例携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者中的临床疗效,发现所有遗传背景患者均有显著时间依赖性改善,但LRRK2携带者2年时所需刺激能量更高,GBA携带者运动和生活质量改善较小。
要点
- STN-DBS对携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者均有显著时间依赖性改善。
- LRRK2携带者2年时所需总电能量更高(时间×基因交互β=94.21,P=0.043)。
- GBA携带者运动改善(vs LRRK2 β=-24.94,P=0.001;vs Parkin/PINK1/DJ1 β=-23.61,P=0.008)和PDQ-39改善(β=-22.67,P=0.018)较小。
核心结论
- STN-DBS对携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者均有获益,但LRRK2携带者可能随时间需要增加刺激,而GBA携带者运动和生活质量改善较小。
研究设计与样本
- 比较18例携带GBA(n=3)、LRRK2(n=9)或Parkin/PINK1/DJ1(n=6)突变的帕金森病患者接受STN-DBS的结局。
- 在基线、程控启动、术后6个月、1年和2年评估左旋多巴等效日剂量、MDS-UPDRS Part III、PDQ-39和总电能量。
- 采用线性混合模型分析纵向和组间差异。
主要发现
- 所有组均显示显著时间依赖性改善。
- 左旋多巴等效日剂量在DBS后急剧下降(1年时最大降低:β=-577.33,P<0.001)。
- MDS-UPDRS Part III评分在程控启动时改善(β=-35.00,P<0.001)并稳定2年。
- PDQ-39评分从6个月起改善(β=-27.67,P<0.001)。
- 总电能量逐渐增加,LRRK2携带者2年时需要更高刺激(时间×基因交互:β=94.21,P=0.043)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The impact of deep brain stimulation of the subthalamic nucleus (STN-DBS) on patients with Parkinson disease (PD) with different genetic risk factors/causes remains uncertain. This study aimed to compare the clinical efficacy of STN-DBS in these patients. METHODS: This study compared STN-DBS outcomes in 18 PD patients with mutations in glucosylceramidase beta (GBA) (n = 3), leucine-rich repeat kinase 2 (LRRK2) (n = 9), or Parkin RBR E3 ubiquitin ligase/PTEN-induced kinase 1/DJ1 (n = 6). Clinical measures-levodopa equivalent daily dose, Movement Disorder Society Unified-Parkinson Disease Rating Scale Part III, Parkinson's Disease Questionnaire-39 (PDQ-39), and total electrical energy delivered-were assessed at baseline, programming initiation, 6 months, 1 year, and 2 years postsurgery. Linear mixed models analyzed longitudinal and intergroup differences. RESULTS: All groups showed significant time-dependent improvements. Levodopa equivalent daily dose dropped sharply post-DBS (maximal reduction at 1 year: β = -577.33, P < 0.001). Movement Disorder Society Unified-Parkinson Disease Rating Scale Part III scores improved by programming initiation (β = -35.00, P < 0.001) and remained stable for 2 years. PDQ-39 scores improved from 6 months onward (β = -27.67, P < 0.001). Total electrical energy delivered increased gradually, with LRRK2 carriers requiring higher stimulation by 2 years (time × gene interaction: β = 94.21, P = 0.043). Main effects revealed GBA carriers had smaller motor improvements (vs. LRRK2: β = -24.94, P = 0.001; vs. Parkin RBR E3 ubiquitin ligase/PTEN-induced kinase 1/DJ1: β = -23.61, P = 0.008) and lesser PDQ-39 gains (β = -22.67, P = 0.018). CONCLUSIONS: STN-DBS demonstrated benefits for patients with PD across all genetic backgrounds, but LRRK2 carriers may require increasing stimulation over time, while GBA carriers show reduced motor and quality-of-life improvements.
引用
- Wu S, Cen Z, Zheng X, et al. Investigation of the Impact of Deep Brain Stimulation of the Subthalamic Nucleus on Parkinson Disease Patients with Genetic Risk Factors/Causes. World Neurosurg. 2025. PMID: 40294793. doi:10.1016/j.wneu.2025.124021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。